These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1127 related items for PubMed ID: 16634900

  • 1. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
    Cowden AL, Katz KA.
    Br J Dermatol; 2006 May; 154(5):950-8. PubMed ID: 16634900
    [Abstract] [Full Text] [Related]

  • 2. Direct-to-consumer advertising affects provider / patient relationship.
    Contracept Technol Update; 1998 Dec; 19(12):153-5. PubMed ID: 12321805
    [Abstract] [Full Text] [Related]

  • 3. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
    Stewart KA, Neumann PJ.
    Value Health; 2002 Dec; 5(5):390-7. PubMed ID: 12201856
    [Abstract] [Full Text] [Related]

  • 4. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
    Symonds T, Hackford C, Abraham L.
    Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
    [Abstract] [Full Text] [Related]

  • 5. Advertising in dermatology journals: journals' and journal editors' policies, practices, and attitudes.
    Bartus CL, Katz KA.
    J Am Acad Dermatol; 2006 Jul; 55(1):116-22. PubMed ID: 16781302
    [Abstract] [Full Text] [Related]

  • 6. Promotion of prescription drugs to consumers.
    Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM.
    N Engl J Med; 2002 Feb 14; 346(7):498-505. PubMed ID: 11844852
    [Abstract] [Full Text] [Related]

  • 7. FDA actions against health economic promotions, 2002-2011.
    Neumann PJ, Bliss SK.
    Value Health; 2012 Feb 14; 15(6):948-53. PubMed ID: 22999146
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Off label drug promotion.
    Body Posit; 1998 Oct 14; 11(10):11. PubMed ID: 11365909
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Advertisements. FDA orders Abbott to change misleading ads for Norvir.
    AIDS Policy Law; 2004 Jul 02; 19(12):9. PubMed ID: 15282864
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. FDA questions San Francisco HIV/AIDS drug advertisements.
    AIDS Policy Law; 2001 May 11; 16(9):1, 6. PubMed ID: 11668819
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
    Nguyen D, Seoane-Vazquez E, Rodriguez-Monguio R, Montagne M.
    BMC Health Serv Res; 2013 Jan 22; 13():27. PubMed ID: 23339419
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Direct-to-physician and direct-to-consumer advertising: Time to have stringent regulations.
    Kannan S, Gowri S, Tyagi V, Kohli S, Jain R, Kapil P, Bhardwaj A.
    Int J Risk Saf Med; 2015 Jan 22; 27(2):77-83. PubMed ID: 26410010
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.